Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DGP-113
- Development stage
- Preclinical
- Lead developer
- Deargen
01
Overview
DGP-113 is a preclinical oncology drug discovery program from Deargen focused on **triple-negative breast cancer**. Publicly available company pipeline information identifies DGP-113 as a Deargen 4D Program asset at the **Target ID** stage, but does **not disclose** a molecular target, drug modality, formulation, route of administration, or mechanism of action. Based on the available evidence, it should be treated as an early-stage, investigational antineoplastic candidate for TNBC with undisclosed biology.
- Other names
- DGP-113-Deargen-TNBCDGP113-Deargen-TNBCDGP 113-Deargen-TNBC
Beyond the preview
Go deeper on DGP-113.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DGP-113.